Pharmacology, Toxicology and Pharmaceutical Science
Ankylosing Spondylitis
100%
Spondylarthritis
81%
Psoriatic Arthritis
58%
Placebo
55%
Secukinumab
34%
Disease
31%
Tumor Necrosis Factor Inhibitor
29%
Rheumatoid Arthritis
27%
Disease Activity
27%
Ixekizumab
19%
Guselkumab
18%
Psoriasis
18%
Certolizumab Pegol
16%
Golimumab
15%
Adverse Event
14%
Disease Modifying Antirheumatic Drug
13%
Upadacitinib
13%
C Reactive Protein
12%
Tumor Necrosis Factor
10%
Tofacitinib
10%
Disease Activity Score
9%
Biological Product
9%
Clinical Trial
9%
Bimekizumab
9%
Placebo-Controlled Study
8%
Interleukin 17
8%
Physical Disease by Body Function
7%
Inflammation
7%
Infection
6%
Randomized Controlled Trial
6%
Enthesitis
6%
Remission
6%
Symptom
5%
Non-Steroidal Anti-Inflammatory Drug
5%
Systemic Lupus Erythematosus
5%
Methotrexate
5%
Adalimumab
5%
Keyphrases
Ankylosing Spondylitis
60%
Psoriatic Arthritis
37%
Axial Spondyloarthritis (AxSpA)
37%
Placebo
23%
Secukinumab
19%
Spondyloarthritis
17%
Rheumatoid Arthritis
16%
Phase II Study
15%
Disease Activity
14%
Ixekizumab
14%
Non-radiographic Axial Spondyloarthritis
12%
American College of Rheumatology
11%
Systemic Lupus Erythematosus
11%
Tumour Necrosis Factor Inhibitor (TNFi)
11%
Guselkumab
11%
Randomized Placebo-controlled Trial
10%
Bimekizumab
9%
Golimumab
9%
Assessment of SpondyloArthritis International Society
8%
Rheumatology
8%
Upadacitinib
8%
Certolizumab Pegol
8%
Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)
8%
HIV Patients
7%
Patient-reported Outcomes
7%
Interleukin-17 (IL-17)
7%
Uveitis
7%
NOD2
7%
Tofacitinib
6%
Arthritis
6%
Enthesitis
6%
Open-label Extension
6%
Health-related Quality of Life
6%
Shared Decision Making
5%
Tumor Necrosis Factor-α
5%
Tuberculosis
5%
AIDS/HIV
5%
T Cells
5%
Lack of Response
5%
Intravenous Golimumab
5%
Ankylosing Spondylitis Disease Activity Score (ASDAS)
5%
Disease Activity Score
5%
Non-steroidal Anti-inflammatory Drugs (NSAIDs)
5%
Medicine and Dentistry
Spondylarthritis
70%
Ankylosing Spondylitis
41%
Disease
25%
Rheumatology
25%
Psoriatic Arthritis
23%
Placebo
22%
TNF Inhibitor
18%
Rheumatoid Arthritis
14%
Ixekizumab
14%
Disease Activity
14%
Guselkumab
11%
Magnetic Resonance Imaging
9%
Quality of Life
8%
Psoriasis
8%
C Reactive Protein
8%
Certolizumab Pegol
8%
Human Immunodeficiency Virus
7%
Patient-Reported Outcome
7%
Systemic Lupus Erythematosus
7%
Disease Modifying Antirheumatic Drug
7%
Symptom
6%
Post-Hoc Analysis
6%
Upadacitinib
6%
Infection
6%
Adverse Event
5%
Secukinumab
5%
Tumor Necrosis Factor
5%
Bimekizumab
5%
Drug Therapy
5%
Backache
5%
Interleukin 17
5%